EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function

Bruce A C Cree iD, Joseph R Berger, Benjamin Greenberg

CNS Drugs · 2025-06 · 39 (6) · 545-564

DOI: 10.1007/s40263-025-01182-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift CNS Drugs, online erschienen am 03.04.2025. Verfasst von Bruce A C Cree und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, 675 Nelson Rising Lane, #221C, San Francisco…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Antigens, CD20, Antibodies, Monoclonal. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

B-cell depletion with CD20-targeted agents is commonly used for treatment of multiple sclerosis (MS), other autoimmune diseases, and certain hematologic malignancies. Initial apparent success with rituximab in MS and neuromyelitis optica spurred development of the anti-CD20 monoclonal antibody (mAb) therapies ocrelizumab, ofatumumab, and ublituximab as well as the anti-CD19 mAb inebilizumab. While each are effective at targeting and depleting B cells, structural differences translate into different mechanisms of action affecting maintenance of B-cell depletion and safety and tolerability. Although the anti-CD20 mAbs differ in degree of human versus mouse sequences as well as target CD20 epitope, these properties do not appear to substantially affect activity or tolerability. In contrast, an antibody-dependent cell-mediated cytotoxicity (ADCC) versus a complement-dependent cytotoxicity mechanism of action as well as subcutaneous versus intravenous administration may provide improved tolerability. Glycoengineering of the mAbs ublituximab and inebilizumab enhances ADCC and can overcome the reduced responses to mAb-mediated B-cell depletion associated with certain genetic polymorphisms. Other strategies for therapeutic targeting of CD20, including brain shuttle antibodies (e.g., RO7121932), bispecific antibodies, chimeric antigen receptor T-cell therapies, and antibody-drug conjugates, are in active clinical development and may be future treatment approaches in MS and other B-cell-mediated autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisAntigens, CD20Antibodies, MonoclonalHumansAnimalsB-LymphocytesAntibody-Dependent Cell Cytotoxicity

Substanzen

Antigens, CD20Antibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, 675 Nelson Rising Lane, #221C, San Francisco, CA, 94158, USA. bruce.cree@ucsf.edu.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
  • Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

ORCID-Profile: Bruce A C Cree

Zitieren

APA

Cree, B. A. C., Berger, J. R., & Greenberg, B. (2025). The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function. CNS Drugs, 39(6), 545-564. https://doi.org/10.1007/s40263-025-01182-8

Vancouver

Cree BAC, Berger JR, Greenberg B. The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function. CNS Drugs. 2025;39(6):545-564. doi:10.1007/s40263-025-01182-8

BibTeX
@article{Cree2025,
  author = {Cree, Bruce A C and Berger, Joseph R and Greenberg, Benjamin},
  title = {The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function},
  journal = {CNS Drugs},
  year = {2025},
  volume = {39},
  number = {6},
  pages = {545--564},
  doi = {10.1007/s40263-025-01182-8}
}
Kostenlos starten →